CY1121639T1 - Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων - Google Patents

Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων

Info

Publication number
CY1121639T1
CY1121639T1 CY20191100534T CY191100534T CY1121639T1 CY 1121639 T1 CY1121639 T1 CY 1121639T1 CY 20191100534 T CY20191100534 T CY 20191100534T CY 191100534 T CY191100534 T CY 191100534T CY 1121639 T1 CY1121639 T1 CY 1121639T1
Authority
CY
Cyprus
Prior art keywords
compositions containing
present
containing nucleotide
compounds
oligonucleotide prodrugs
Prior art date
Application number
CY20191100534T
Other languages
English (en)
Inventor
Radhakrishnan P. Iyer
Seetharamaiyer Padmanabhan
Original Assignee
Spring Bank Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals, Inc. filed Critical Spring Bank Pharmaceuticals, Inc.
Publication of CY1121639T1 publication Critical patent/CY1121639T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει ενώσεις του τύπου (I): οι οποίες επιδεικνύουν αντιϊικές ιδιότητες. Η παρούσα εφεύρεση περαιτέρω αφορά φαρμακευτικές συνθέσεις οι οποίες περιέχουν τις ανωτέρω αναφερόμενες ενώσεις για χορήγηση σε ένα υποκείμενο που χρήζει αντι-HBV θεραπευτικής αγωγής. Η εφεύρεση αφορά επίσης μεθόδους θεραπευτικής αγωγής λοίμωξης HBV σε ένα υποκείμενο μέσω χορήγησης φαρμακευτικής σύνθεσης που περιέχει τις ενώσεις της παρούσας εφεύρεσης.
CY20191100534T 2005-12-13 2019-05-20 Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων CY1121639T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs
PCT/US2006/047617 WO2007070598A2 (en) 2005-12-13 2006-12-13 Nucleotide and oligonucleotide prodrugs
EP06848625.7A EP1968612B1 (en) 2005-12-13 2006-12-13 Dinucleotide prodrugs

Publications (1)

Publication Number Publication Date
CY1121639T1 true CY1121639T1 (el) 2020-07-31

Family

ID=38194676

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100388T CY1117576T1 (el) 2005-12-13 2016-05-09 Δινουκλεοτιδικα προφαρμακα
CY20191100534T CY1121639T1 (el) 2005-12-13 2019-05-20 Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100388T CY1117576T1 (el) 2005-12-13 2016-05-09 Δινουκλεοτιδικα προφαρμακα

Country Status (17)

Country Link
US (6) US8076303B2 (el)
EP (3) EP1968612B1 (el)
JP (1) JP5044854B2 (el)
KR (2) KR101123534B1 (el)
CN (2) CN101437397B (el)
CY (2) CY1117576T1 (el)
DK (2) DK1968612T3 (el)
ES (2) ES2729657T3 (el)
HR (1) HRP20160531T1 (el)
HU (2) HUE044034T2 (el)
IN (1) IN2015DN01786A (el)
LT (1) LT3090748T (el)
PL (2) PL1968612T3 (el)
PT (1) PT3090748T (el)
RS (1) RS54867B1 (el)
SI (2) SI3090748T1 (el)
WO (1) WO2007070598A2 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292973T1 (de) * 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN102123716B (zh) * 2008-04-03 2013-09-18 春堤公司 用于治疗病毒感染的化合物和方法
EP3067359A1 (en) * 2008-09-23 2016-09-14 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
WO2010072831A1 (en) * 2008-12-23 2010-07-01 Girindus America, Inc Sulfurizing reagents and their use for oligonucleotides synthesis
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
AU2010270714B2 (en) * 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
CN101659612B (zh) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 一种选择性酯化的方法
WO2012030626A2 (en) * 2010-08-30 2012-03-08 Spring Bank Pharmaceuticals, Inc. Design of oligonucleotide analogs as therapeutic agents
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
KR101327026B1 (ko) 2011-11-29 2013-11-13 현대자동차주식회사 운전자 보호장치
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
SG11201500232UA (en) * 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
AU2014217892B2 (en) * 2013-02-18 2018-11-22 Spring Bank Pharmaceuticals, Inc. Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10160969B2 (en) * 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
EP3197459A4 (en) * 2014-09-28 2018-06-20 Huahui Health Ltd. Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
WO2016164625A1 (en) * 2015-04-07 2016-10-13 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
CA2991156A1 (en) * 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
WO2017156391A1 (en) * 2016-03-11 2017-09-14 Spring Bank Pharmaceuticals, Inc. Compounds and compositions for the treatment of infections
MX2019000660A (es) * 2016-07-15 2019-10-02 Sperovie Biosciences Inc Compuestos, composiciones y métodos para el tratamiento de enfermedades.
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051489A1 (en) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CN110467646A (zh) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物
CN110467647B (zh) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物的制备方法
WO2019219070A1 (zh) * 2018-05-18 2019-11-21 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
SG11202011434SA (en) 2018-06-01 2020-12-30 Eisai R&D Man Co Ltd Methods for the treatment of bladder cancer
FR3082434B1 (fr) 2018-06-14 2021-04-30 Cairdac Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique
US11691990B2 (en) 2018-08-16 2023-07-04 Eisai R&D Management Co., Ltd Salts of compounds and crystals thereof
WO2020092617A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
WO2020114495A1 (zh) * 2018-12-06 2020-06-11 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法
CN111484540B (zh) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 含双核苷酸结构的化合物
JP7421280B2 (ja) 2019-07-30 2024-01-24 三和シヤッター工業株式会社 建具

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041A1 (de) 1978-04-19 1979-10-31 Reich Maschf Gmbh Karl Verfahren und vorrichtung zum aufteilen von platten
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
JPH05506033A (ja) 1990-04-18 1993-09-02 ノーウィッチ、イートン、ファーマスーティカルズ、インコーポレーテッド 抗微生物性キノロニルラクタム類
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
WO1998007734A1 (en) 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
DK2415776T3 (en) 1998-08-10 2016-07-04 Novartis Ag Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
DK2682397T3 (da) 2000-07-21 2017-06-19 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JP2005525991A (ja) * 2001-05-16 2005-09-02 マイジェニックス インコーポレイテッド 核酸ベースの化合物およびその使用方法
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (zh) 2006-09-15 2011-04-20 华为技术有限公司 新接入节点随机接入的方法及其系统
CN102123716B (zh) * 2008-04-03 2013-09-18 春堤公司 用于治疗病毒感染的化合物和方法

Also Published As

Publication number Publication date
RS54867B1 (sr) 2016-10-31
KR20110125677A (ko) 2011-11-21
DK1968612T3 (en) 2017-05-22
CN101437397B (zh) 2012-09-05
EP1968612A4 (en) 2013-01-09
JP2009519345A (ja) 2009-05-14
HUE044034T2 (hu) 2019-09-30
CY1117576T1 (el) 2017-04-26
DK3090748T3 (da) 2019-05-27
HUE029190T2 (en) 2017-02-28
US10344046B2 (en) 2019-07-09
US20140323554A1 (en) 2014-10-30
US20160060287A1 (en) 2016-03-03
KR101123534B1 (ko) 2012-03-13
US20200087338A1 (en) 2020-03-19
KR20080072084A (ko) 2008-08-05
US20180273574A1 (en) 2018-09-27
CN101437397A (zh) 2009-05-20
ES2729657T3 (es) 2019-11-05
PL1968612T3 (pl) 2016-11-30
US8076303B2 (en) 2011-12-13
IN2015DN01786A (el) 2015-07-10
HRP20160531T1 (hr) 2016-08-12
US20120264709A1 (en) 2012-10-18
CN102796155B (zh) 2015-08-26
EP1968612A2 (en) 2008-09-17
EP1968612B1 (en) 2016-03-09
SI1968612T1 (sl) 2016-10-28
EP3553072A1 (en) 2019-10-16
PL3090748T3 (pl) 2020-03-31
WO2007070598A2 (en) 2007-06-21
JP5044854B2 (ja) 2012-10-10
PT3090748T (pt) 2019-06-04
EP3090748B1 (en) 2019-02-20
CN102796155A (zh) 2012-11-28
WO2007070598A8 (en) 2008-12-31
US10047114B2 (en) 2018-08-14
US20070149462A1 (en) 2007-06-28
EP3090748A1 (en) 2016-11-09
WO2007070598A3 (en) 2008-10-30
US8691787B2 (en) 2014-04-08
ES2573928T3 (es) 2016-06-13
LT3090748T (lt) 2019-08-26
KR101248873B1 (ko) 2013-04-02
WO2007070598A9 (en) 2007-11-08
SI3090748T1 (sl) 2019-09-30

Similar Documents

Publication Publication Date Title
CY1121639T1 (el) Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων
CY1119988T1 (el) Αναστολεις του ιου της ηπατιτιδας c
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
MA32787B1 (fr) Peptides antiviraux therapeutiques
CY1115253T1 (el) Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
UY28084A1 (es) Derivados antivirales de nucleosidos
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
DK1819227T3 (da) Farmaceutisk formulering af decitabin
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
CY1113890T1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
ATE547417T1 (de) Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
TW200517389A (en) Biaryloxymethylarenecarboxylic acids
EA200970375A1 (ru) Соединения и способы лечения вируса гепатита с
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων